Extensive-stage Small-cell Lung Cancer Clinical Trials in Chengdu, Sichuan
4 recruitingChengdu, Sichuan, China
Showing 1–4 of 4 trials
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Extensive-stage Small-cell Lung Cancer
Bristol-Myers Squibb530 enrolled183 locationsNCT06646276
Recruiting
Phase 3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Small Cell Lung CancerExtensive-stage Small-cell Lung Cancer
Amgen330 enrolled158 locationsNCT07005128
Recruiting
Phase 1Phase 2
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Lung CancerExtensive-stage Small-cell Lung Cancer
Sichuan University45 enrolled1 locationNCT06217757
Recruiting
Phase 2
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
Extensive-stage Small-cell Lung Cancer
Sichuan University61 enrolled8 locationsNCT05765825